Cyanide: critical issues in diagnosis and treatment

Human and Experimental Toxicology - Tập 26 Số 3 - Trang 191-201 - 2007
Frédéric J. Baud1
1Department of Medical and Toxicological Critical Care, University Paris 7, INSERM U705, France

Tóm tắt

The concern of a terrorist attack using cyanide, as well as the gradual awareness of cyanide poisoning in fire victims, has resulted in a renewed interest in the diagnosis and treatment of cyanide poisoning. The formerly academic presentation of cyanide poisoning must be replaced by more useful knowledge, which will allow emergency physicians and rescue workers to strongly suspect cyanide poisoning at the scene. Human cyanide poisonings may result from exposure to cyanide, its salts, or cyanogenic compounds, while residential fires are the most common condition of exposure. In fire victims, recognition of the cyanide toxidrome has been hampered by the short half-life in blood and poor stability of cyanide. In contrast, carboxyhemoglobin, as a marker of carbon monoxide poisoning, is easily measured and long-lasting. No evidence supports the assumption of the arbitrary fixed lethal thresholds of 50% for carboxyhemoglobin, and 3 mg/L for cyanide, in fire victims. Preliminary data, drawn when comparing pure carbon monoxide and pure cyanide poisonings, suggest that a cyanide toxidrome can be defined considering signs and symptoms induced by cyanide and carbon monoxide, respectively. Prospective studies in fire victims may provide value in clarifying signs and symptoms related to both toxicants. Cyanide can induce a lifethreatening poisoning from which a full recovery is possible. A number of experimentally efficient antidotes to cyanide exist, whose clinical use has been hampered due to serious side effects. The availability of potentially safer antidotes unveils the possibility of their value as first-line treatment, even in a complex clinical situation, where diagnosis is rapid and presumptive.

Từ khóa


Tài liệu tham khảo

Hall AH, 1987, Clinical and experimental toxicology of cyanides, 312

Borron SW, 1996, Arhiv za Higijenu Rada i Toksikologiju, 47, 307

Curry SC, 2005, Critical care toxicology. Diagnosis and management of the critically poisoned patient, 987

10.1056/NEJMra030370

Bryson D., 1987, Clinical and experimental toxicology of cyanides, 348

10.1016/S0196-0644(98)70077-0

10.1056/NEJM197804132981502

10.1016/0736-4679(87)90074-6

Ballantyne B, 1987, Clinical and experimental toxicology of cyanides, 217

10.1080/20024091064246

10.1081/CLT-200035211

10.1097/00003246-200209000-00015

10.1056/NEJM199112193252502

10.1039/b009493p

10.1081/ESE-100102619

10.1520/JFS14314J

10.1093/jat/26.6.320

10.1016/S1344-6223(02)00094-9

10.1016/0378-4274(92)90196-Q

10.1016/0378-4274(92)90197-R

Targosz D, 1999, Przeglad Lekarski, 56, 415

10.1056/NEJM199811263392206

10.1016/S0140-6736(89)90592-8

10.1081/CLT-100102880

Akkose S, 2005, Clin Toxicol, 43, 105

10.1081/CLT-120022001

10.1177/096032719601501106

Lapostolle F, 2001, Ann Fr Anesth Reanim, 20, 10, 10.1016/S0750-7658(00)00340-3

10.1258/000456302760042146

Moureu H, 1957, Arch Malad Prof (Paris), 18, 116

Gourlain H, 1998, Presse Méd, 28, 163

10.1378/chest.117.3.801

Haldane J, 1935, Respiration

10.1007/BF02332342

Meredith T, 1992, IPCS/CEC evaluation of antidotes series, 1

Barois A, 1979, Rev Pratic, 29, 1211

Blettery B, 1983, Ann Méd Int (Paris), 134, 99

10.1016/S0196-0644(85)81023-4

10.1191/096032799678839455

O'Brien B, 2005, Eur J Emerg Med, 12, 257, 10.1097/00063110-200510000-00014

Meigs JW, 1952, AMA Arch Ind Hyg Occup Med, 6, 344

10.1016/S0079-6123(08)60180-6

10.1177/096032718300200226

10.1016/0735-6757(95)90162-0

Goulon M, 1969, Ann Méd Inter (Paris), 120, 335

10.1007/s00134-003-1866-0

10.7326/0003-4819-82-6-803

Bogusz M, 1972, Eur J Toxicol Hyg Environ, 5, 306

10.1007/BF00353317

Leikin JB, 1980, Vet Hum Toxicol, 30, 40

10.1097/00003246-198902000-00007

10.1007/BF00290887

Gracey DR, 1974, Heart Lung, 3, 817

10.1542/peds.104.3.e34

10.1097/00005373-197602000-00006

Lebby TI, 1989, Vet Hum Toxicol, 31, 138

Bismuth C, 1984, Presse Méd, 13, 2493

10.1146/annurev.pa.24.040184.002315

10.1002/j.1552-4604.1992.tb03849.x

Evans CL, 1964, Br J Pharmacol, 23, 455

10.1097/00008506-199012000-00008

10.1016/S0140-6736(95)91437-4

10.3109/15563659309000395

10.1007/BF01709274

Fortin JL, 2004, JEMS: J Emerg Med Serv, 29, S18

Hall AH, 1989, J Toxicol Clin Exp, 9, 3

10.1001/archinte.1977.03630200055016

10.1007/BF01693704

10.1016/0736-4679(94)90359-X

10.1001/jama.290.15.2041

10.1097/00075198-200306000-00006

Rachinger J, 2002, Am J Neuroradiol, 23, 1398

Thông tin
Thông tin xuất bản

Human and Experimental Toxicology

Tập 26 Số 3

191-201

Thông tin tác giả